{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:15Z","timestamp":1789726335012,"version":"4.0.1"},"reference-count":19,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T00:00:00Z","timestamp":1205280000000},"content-version":"vor","delay-in-days":6311,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[1990,12]]},"abstract":"<jats:p><jats:bold>S<jats:sc>ummary<\/jats:sc><\/jats:bold> Early institution of empiric therapy with a broad\u2010spectrum antibiotic has markedly reduced the morbidity and mortality from infections complicating severe or prolonged cytopenia in patients receiving either an allogeneic or autologous hone marrow transplant. Ceftazidime in combination with an aminoglycoside, i.e. netilmicin, has been established as a combination schedule offering low or even avoiding therapy\u2010related toxicity.<\/jats:p><jats:p>We evaluated teicoplanin for suspected Gram\u2010positive infections after inadequate response to initial beta\u2010lactam and aminoglycoside combination therapy. All 11 patients so far included in this study received either an allogeneic (five patients) or an autologous (six patients) bone marrow transplant for acute myeloid leukaemia (AML). non\u2010Hodgkin lymphoma (NHL. high grade) or other malignant diseases. All patients developing a primary septicaemia of unknown origin (10 patients) or a catheter related septicaemia (one patient) were treated with 400 mg teicoplanin, administered i.v. once daily in combination with a cephalosporin and an aminoglycoside (ceftazidime 2 g. i.v., t.i.d., netilmicin 400 mg once daily). All 11 patients responded to therapy. 10 patients were clinically cured, one patient improved under therapy. The therapeutic regimen was well tolerated and adverse drug reactions did not occur. We have not observed any delayed take or prolonged neutropenia or thrombocytopenia with this therapeutic regimen when compared to other bone marrow transplant patients who did not receive this antimicrobial therapy.<\/jats:p><jats:p>Our preliminary results suggest that teicoplanin is a potentially effective and well\u2010tolerated antimicrobial agent in bone marrow transplant patients with infections not responding primarily to beta\u2010lactams and aminoglycosides.<\/jats:p>","DOI":"10.1111\/j.1365-2141.1990.tb07929.x","type":"journal-article","created":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T11:09:40Z","timestamp":1205320180000},"page":"14-18","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A clinical trial on efficacy and safety of teicoplanin in combination with beta\u2010lactams and aminoglycosides in the treatment of severe sepsis of patients undergoing allogeneic\/autologous bone marrow transplantation"],"prefix":"10.1111","volume":"76","author":[{"given":"E.","family":"Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Schmid","family":"And","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Fauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,12]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1983.tb02100.x"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/154.2.349"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.1126"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/21.suppl_A.1"},{"issue":"9","key":"e_1_2_1_6_1","first-page":"841","article-title":"Haematologic recovery following autologous and allogeneic bone marrow transplantation","volume":"11","author":"Harada M.","year":"1983","journal-title":"Experimental Haematology"},{"issue":"5","key":"e_1_2_1_7_1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood.V73.5.1340.1340","article-title":"Immune reconstitution following bone marrow transplantation: comparison of recipients of conventional marrow grafts","volume":"73","author":"Keever C.A.","year":"1989","journal-title":"Blood"},{"issue":"5","key":"e_1_2_1_8_1","first-page":"2","article-title":"Concept of empiric therapy with antibiotic combinations. Indications and limits","volume":"80","author":"Klastersky J.","year":"1986","journal-title":"American Journal of Medicine"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/21.suppl_A.113"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0002-9343(86)90511-5","article-title":"Infections in bone marrow transplant recipients","volume":"81","author":"Meyers J.D.","year":"1984","journal-title":"American Journal of Medicine"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/11.5.419"},{"key":"e_1_2_1_12_1","first-page":"343","volume-title":"Current Chemotherapy and Immunotherapy","author":"Somma S.","year":"1982"},{"key":"e_1_2_1_13_1","first-page":"974","article-title":"Progenitor cell numbers (CFU\u2010GM. CFU\u2010D and CFU\u2010Mix) and haemopoietic recovery following autologous marrow transplantation","volume":"17","author":"Stewart F.M.","year":"1989","journal-title":"Experimental Haematology"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/21.suppl_A.69"},{"issue":"5","key":"e_1_2_1_15_1","first-page":"12","article-title":"Comparative in vitro study of the activity of teiehomycin. vancomycin and N\u2010formimidoyl\u2010thienamycin on Staphylococcus aureus","volume":"2","author":"Thabaut A.","year":"1983","journal-title":"Chemioterapia"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059273"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.6.881"},{"issue":"6","key":"e_1_2_1_18_1","first-page":"491","article-title":"Teicoplanin for therapy of Gram\u2010positive infections in neutropenic patients","volume":"7","author":"Verhagen C.","year":"1987","journal-title":"International Journal of Clinical Pharmaceutical Research"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0195-6701(87)90036-3"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198608283150910"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.1990.tb07929.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.1990.tb07929.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T14:09:00Z","timestamp":1695737340000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.1990.tb07929.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,12]]},"references-count":19,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[1990,12]]}},"alternative-id":["10.1111\/j.1365-2141.1990.tb07929.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.1990.tb07929.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,12]]},"assertion":[{"value":"2008-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}